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Background: Formoterol fumarate (FF) is a well-established long-acting b2-agonist. This repre-
sents the first clinical study of FF in a metered-dose inhaler (FF MDI) based on proprietary lipid-
based porous-particle engineering technology.
Methods: In this randomized, double-blind, 5-period, crossover study (NCT00880490), subjects
received 2.4, 4.8, and 9.6 mg of FF MDI, open-label Foradil Aerolizer (FA) 12 mg, and placebo.
Spirometry was performed at baseline, 15 and 30 min, and 1, 2, 4, 6, 8, 10, 11.5, and 12 h post-
dose.
Results: Thirty-four subjects were enrolled. Improvement in forced expiratory volume in 1 s
(FEV1) was similar between FF MDI 9.6 mg and FA. Change in FEV1 area under the curve for 0
e12 h (AUC0e12) for each FF MDI dose demonstrated superior efficacy versus placebo
(P < .001 for all 3 doses). Over 12 h and at each time point, FF MDI 9.6 mg was non-inferior
to FA for FEV1 AUC0e12 with the 95% CI’s supporting a maximum difference of approximately
45 mL. Peak and trough FEV1, forced vital capacity, peak expiratory flow rate, peak inspiratory
capacity, and pharmacokinetics confirmed the primary endpoint, with dose ordering of the FF
MDI 2.4, 4.8, and 9.6 mg, and comparability of FF MDI 9.6 mg to FA. All 3 doses of FF MDI were
safe and well-tolerated, with a safety profile similar to that of placebo and FA.801 0002; fax: þ64 4 389 7468.
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1328 D. Quinn et al.Conclusions: The efficacy and pharmacokinetic profile of FF MDI 9.6 mg were comparable to FA
12 mg and with similar safety to placebo and FA.
Trial registration: This clinical trial was registered on ClinicalTrials.gov, Identifier: NCT
NCT00880490.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Bronchodilator medications are central to alleviating the
characteristic airflow limitation of chronic obstructive
pulmonary disease (COPD) [1]. Metered-dose inhalers (MDIs)
are the most commonly used devices to deliver broncho-
dilator treatment to patients with COPD and asthma [2].
Although they are easy to use and well-accepted, the
reformulating of MDI products with hydrofluoroalkane (HFA)
propellants that comply with stricter environmental regu-
lations [3] has posed technical challenges.
HFA MDIs formulated upon a porous-particle platform
using a spray-drying method provide a scaffold for suspen-
sions of inhaled drugs, leading to improved physical sta-
bility, the ability to formulate at very low doses, consistent
dose-to-dose performance, high fine-particle fraction
(FPF), and improved delivery of drug to the lower respira-
tory tract with minimized oropharyngeal exposure [4e6].
Formoterol fumarate (FF) is a well-established and
extensively tested long-acting b2-adrenergic receptor
agonist (LABA) indicated for the management of asthma and
COPD, with Foradil Aerolizer 12 mg (FA; Merck &Co., Inc.,
Whitehouse Station, NJ, USA) twice daily (BID) being the
approved dose in the United States. This study represents
the first clinical study of FF in a metered-dose inhaler (FF
MDI) based on proprietary lipid-based porous-particle engi-
neering technology. It is postulated that this experimental
FF MDI will result in improved lung function as assessed from
FEV1 outcomes over a 12-h period compared with placebo.
It is anticipated that this formulation of FF MDI may
provide advantages over currently available formulations at
the same or lower doses in a patient cohort with moderate
to severe COPD (GOLD definition [1]), particularly when co-
formulated with a long-acting antimuscarinic agent (LAMA),
and with an inhaled corticosteroid as a triple therapy. The
study was designed to evaluate the single-dose adminis-
tration of 3 doses of FF MDI in patients with moderate-to-
severe COPD compared with open-label FA 12 mg as an
active control in order to determine a dose that provides
comparable bronchodilation and that does not exceed the
systemic exposure.Methods
Study design
This randomized, double-blind, 5-period, placebo- and
active-controlled, crossover, multicenter study was con-
ducted at clinical study centers in Australia and NewZealand between November 2008 and May 2009. The pri-
mary objective of the study was to assess the effects
following a single dose of FF MDI in doses of 2.4, 4.8, and
9.6 mg on forced expiratory volume in the first second
(FEV1) area under the curve from 0 to 12 h (AUC0e12)
compared with open-label FA 12 mg and placebo among
study patients with moderate-to-severe COPD. Secondary
objectives included a) the assessment of a change from
test-day baseline in mean peak FEV1, mean peak expiratory
flow rate (PEFR), mean forced vital capacity (FVC), trough
FEV1 (tFEV1), and mean peak inspiratory capacity (IC); b)
confirm non-inferiority by comparing FF MDI with FA 12 mg
based on change in FEV1 AUC0e12; c) assess the safety
profile; and d) to define a dose of FF MDI that provided
comparable systemic concentrations to open-label FA
12 mg. Approvals were obtained from institutional ethics
committees at each investigator site. Written informed
consent was obtained from each study patient prior to
entry into the trial. The study was listed on all appropriate
clinical trial registries including the United States (US)
National Institutes of Health’s ClinicalTrials.gov
(NCT00880490) as well as the Australia/New Zealand Clin-
ical Trial Registry (ACTRN12609000191291).
Study patient population
Males and females, aged 40 to 80 years with a cigarette-
smoking history of at least 10 pack-years, and an estab-
lished clinical history of COPD in accordance with the
American Thoracic Society (ATS)/European Respiratory So-
ciety (ERS) definition [7] were eligible for study participa-
tion. Study patients also were required to demonstrate
reversibility to a short-acting b-agonist (SABA); defined as
>12% and >150 mL improvement in baseline FEV1 30 min
following administration of 4 puffs of salbutamol MDI, or
>200 mL improvement in baseline FEV1 30 min following
administration of 4 puffs of salbutamol MDI. Exclusion
criteria included a primary diagnosis of asthma, poorly
controlled COPD, active tuberculosis, lung cancer, other
active pulmonary disease or clinically significant medical
conditions, and hypersensitivity to any b-agonist or any
component of the MDI and/or constituents of the dry
powder product (lactose). Study patients were randomly
allocated using a permuted block randomization algorithm.
Assessment of bronchodilator response
Both forced expiratory spirometry for derivation of FEV1,
FVC, and PEFR, and slow vital capacity maneuvers for IC
determination were assessed using a spirometer that met or
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ATS. At Randomization, spirometry was conducted 1 h and
0.5 h prior to study drug administration. The average of
these 2 assessments was used to establish test day baseline
FEV1, FVC, and PEFR. Following study drug administration,
spirometry was obtained at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 11.5,
and 12 h post-dosing. FEV1, FVC, and PEFR data were
analyzed for primary and secondary assessments.
IC assessments were obtained on 6 occasions immedi-
ately prior to standard spirometry assessments: baseline
(the average of the assessments at 1 h and 0.5 h), 1, 2,
11.5, and 12 h post-dose. Change in peak IC compared with
placebo was a key secondary endpoint. During post-
randomization study visits, spirometry was obtained at
the same time points as outlined for Visit 2. The baseline
FEV1 on each test day must have been within 15% of the
baseline FEV1 obtained at randomization (Visit 2). If the
test day FEV1 was not within 15% of randomization FEV1,
the visit could be rescheduled at the investigator’s discre-
tion or the patient discontinued.Study treatments
Treatments consisted of FF MDI in a porous-particle
formulation suspended in an HFA propellant in strengths
of 3, 6, and 12 mg ex-valve, corresponding to 2.4, 4.8, and
9.6 mg ex-actuator for open-label FA 12 mg, and placebo,
respectively. One dose concentration of test product (FF
MDI) was used during this study. That is, each actuation
released 3 mg (ex-valve) of the test product, which corre-
sponded to a therapeutic amount of approximately 2.4 mg
(ex-actuator), with multiple inhalations to achieve the
different doses. In order to maintain blinding, it was
necessary for study patients to inhale study drug from two
different MDIs on each test day.
Prior to randomization, all study patients treated with
inhaled corticosteroids (ICS) in combination with LABA or a
LAMA discontinued those medications and were provided
salbutamol MDI, ipratropium MDI, or a combination of
ipratropium/salbutamol MDI per physician discretion.
Theophylline in any formulation was discontinued. Study
patients underwent a washout period of at least 1 week,
but no longer than 4 weeks prior to the initiation of study
medication. Study patients were asked to withhold all COPD
medications for at least 8 h prior to study visits. There was
at least 3 days and no more than 10 days between doses.
Between test days, study patients resumed their previous
COPD medications as defined at the Screening Visit. Sub-
jects and all study-related staff were blinded to study pa-
tient assignment. This applied to the FF MDI and placebo
treatments; FA 12 was open-label. Emphron Informatics Pty
Ltd prepared the randomization scheme that was used to
allocate patients to a study treatment sequence.Stopping criteria
A study patient was to be discontinued from participation if
any of the following parameters or clinical signs were noted
on 2 consecutive assessments conducted approximately
15 min apart at the discretion of the principal investigator: QTcF prolongation greater than 30 ms from test day
baseline and >430 msec
 Heart rate (HR): 40 bpm greater than test day baseline
and an HR > 120 bpm
 HR: 20 bpm lower than test day baseline and an
HR < 45 bpm
 Systolic blood pressure (BP): 40 mmHg greater than test
day baseline and a systolic BP > 160 mmHg
 Systolic BP: 20 mmHg lower than test day baseline and a
systolic BP < 90 mmHg
 Diastolic BP: 20 mmHg greater than test day baseline and
a diastolic BP > 110 mmHg
 Diastolic BP: 20 mmHg lower than test day baseline and
diastolic BP < 60 mmHg
 FEV1: greater than 20% decrease from test day baseline
on two consecutive spirometry assessments obtained at
least 15 min apart with associated symptoms of dyspneaDetermination of sample size
Power was calculated assuming a non-central t distribution
for the relevant linear contrast and under the assumption
that a Bonferroni correction would be applied. An effect
size of 160 mL was assumed, which was considered con-
servative given the results of Dahl et al. [8] and Gross et al.
[9]. Power calculations also assumed a within subjects
standard deviation of 200 mL [10]. Based on these calcu-
lations, 25 study patients with moderate to severe revers-
ible COPD were required to achieve a power of 90% for
detecting a change in FEV1 AUC0e12.
Statistical analysis
Demographic and safety analyses were based on the intent-
to-treat (ITT) population, which included all study patients
who were randomized and received at least one dose of
study treatment. A modified ITT (mITT) population was
used for the analysis of pharmacokinetic (PK), pharmaco-
dynamic (PD), and efficacy variables and included study
patients who remained in the study for at least 6 h post-
dosing. Repeated measures analysis of variance (ANOVA)
was performed in which treatment was a fixed-effect, and
within patient-errors were correlated (unstructured, com-
pound symmetry and AR (1) models were considered;
compound symmetry was selected because it gave the
best overall Akaike Information Criterion (AIC) [11] but
between-patient errors were independent. Treatment
group means and 95% confidence intervals (CI) were tabu-
lated for efficacy variables. Linear contrasts and their
associated 95% CIs were estimated for each dose versus
placebo, and 95% CIs were calculated for the difference FA
12 mg mean minus FF MDI mean for each dose of FF MDI. The
upper limit of this CI represents a reasonable estimate of
the maximum likely difference between treatments. A
negative value for this upper limit would imply that FF MDI
is statistically superior to FA 12 mg. Non inferiority com-
parisons using an a priori defined margin of 100 mL were
conducted for FF MDI in comparison with FA 12 mg. The
margin of 100 mL was selected because this represents a
clinically meaningful difference [12]. Analogous statistical
Table 1 Study patient baseline characteristics (ITT pop-
ulation; N Z 34).
Characteristic Value
Sex, n (%)
Female 16 (47%)
Male 18 (53%)
Age, years
Mean  SD 64.76  8.12
Height, cm
Mean  SD 168.88  8.64
Weight, kg
Mean  SD 79.38  18.34
Race, n
Caucasian 32
Australian/Aboriginal/Islander 0
1330 D. Quinn et al.analyses were conducted for secondary efficacy endpoints.
Mean log PK parameters and 90% CIs of their ratios were
calculated from the mixed-model analysis of variance.
Repeated measures ANOVA were performed in which
treatment was a fixed-effect. Relative bioavailability cal-
culations and 90% CIs for bioequivalence were calculated
from the parameters of the linear repeated measures
analysis. Plasma AUC0e12 and ratio of peak FEV1 to
maximum plasma concentration (Cmax) were calculated
using a linear mixed model with treatment as a fixed-effect
and study patient as a random effect. Adverse events (AEs)
and treatment-emergent adverse events (TEAEs) were
summarized by the number of events and study patients
experiencing each event by treatment. Clinical laboratory
variables, vital signs, and electrocardiograms (ECGs) were
also tabulated.Asian 0
South Asian 1
Smoking history, years
Mean  SD 46.7  29.7
Mean Pre-dose FEV1, L (% pre-dose) 1.35 (46.9%)
Mean Post-dose FEV1, L (% pre-dose) 1.64 (57.0%)
Mean SABA reversibility, L (% pre-dose) 0.29 (10.1%)
FEV1 Z forced expiratory volume in 1 s; ITT Z intent-to-treat;
SD Z standard deviation; SABA Z short-acting b-agonist.Results
Baseline characteristics
In total, 34 study patients were enrolled, 29 of whom
completed the study. The disposition of study patients is
provided in Figure 1. The first enrolled patient served as a
sentinel study patient who was administered treatment and
observed for 24 h after Visits 2, 3, and 4. This sentinel
patient experienced no clinically relevant changes in vital
signs, ECG or spirometry tests, no AEs, and reported no new
concomitant medications. After these observations, dosing
was then opened for additional study patients at all sites.
Demographic data and baseline characteristics are
summarized in Table 1. The mean (SD) age of the studyAssessed for Eligibility
(n=80)
Screen Failures (n=46)
Reasons, n (%) 
•
•
•
•
Failed spirometry entry criteria, 37 (46) 
Concurrent condition, 6 (7.5) 
Taking prohibited medication, 2 (2.5) 
Withdrew consent, 1 (1.3) 
Randomized (n=34)
Completed (n=29) Withdrawn (n=5) 
Reasons, n (%) 
•
•
•
Adverse events, 3 (8.8) 
Defined stopping criteria, 1 (2.9)
Withdrew consent, 1 (2.9) 
Figure 1 Study patient disposition.population was 64.8 (8.1) years (range 41e79 years), sex
was approximately evenly distributed (16 females, 18
males), and 94% of study patients were Caucasian. Twenty-
six percent of study patients were current smokers, and the
mean (SD) smoking history was 46.7 (29.7) pack-years. At
screening, the mean FEV1 was 1.35 L pre-dose (46.9% of
predicted) and 1.64 L post-dose (57.0% of predicted). Mean
SABA reversibility was 0.29 L improvement in FEV1 (10.1%
predicted).Efficacy
Primary endpoint
For the primary efficacy endpoint, change in FEV1 AUC0e12,
each FF MDI dose demonstrated significantly superior effi-
cacy compared with placebo (P < .001 for all 3 doses) with a
clear doseeresponse relationship (Table 2). The normalized
FEV1 AUC0e12 by FF dose for the mITT; (efficacy) population
is represented in Figure 2. In general, compared with the
test-day baseline the mean change in FEV1 over time was
similar between FF MDI 9.6 mg and open-label FA 12 mg, with
nearly identical response curves over time (Figure 3).
Tested with the a priori defined non-inferiority bound of
100 mL [12], FF MDI 9.6 mg was non-inferior to open-label FA
12 mg in terms of improvement from baseline in FEV1 over
12 h and at each time point. Further analyses determined
that the 95% CI’s support a maximum difference of
approximately 45 mL, which provides further validation of
the similar efficacy between the FF MDI 9.6 mg dose and FA
12 mg. The 2.4-and 4.8-mg doses of FF MDI were substanti-
vely lower than FA 12 mg at most time points assessed, and
did not meet the pre-specified non-inferiority criteria for
most of the assessments.
Table 2 Primary efficacy endpoint: mean change in FEV1 AUC0e12 compared with placebo (mITT efficacy population).
Variable FF MDI 2.4 mg FF MDI 4.8 mg FF MDI 9.6 mg
FEV1 AUC0e12 (L), Difference (Mean  SE) 0.0815  0.0185 0.1034  0.0189 0.1759  0.0195
Pa <0.001 <0.001 <0.001
AUC0e12 Z area under the curve for 0e12 h; FEV1 Z forced expiratory volume in 1 s; FF MDI Z formoterol fumarate metered-dose
inhaler; mITT Z modified intent-to-treat; SE Z standard error.
a P values for comparisons with placebo from repeated measures analysis of variance (ANOVA), in which treatment was a fixed-effect,
within-patient errors were correlated, and between-patient errors were independent. Covariates included in the model were age, sex,
height, and test-day baseline.
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In general, the analyses of the secondary endpoints
(including peak and tFEV1, FVC, PEFR, and peak IC)
confirmed the findings of the primary endpoint, with dose-
dependent responses of FF MDI 2.4, 4.8, and 9.6 mg, and the
comparability of FF MDI 9.6 mg to FA 12 mg (Figures 4A, B,
C). Both peak change in FEV1 from test-day baseline andFigure 2 Normalized AUC0e12 FEV1 vs Dose of Formoterol
Fumarate (mITT Efficacy Population).
Figure 3 Mean change in FEV1 over time by treatment
compared with test-day baseline (mITT efficacy population).the mean change in FVC over time were significantly
greater with each of the FF MDI doses compared with pla-
cebo. FF MDI 2.4, 4.8, and 9.6 mg demonstrated dose-
ordering for the peak change from baseline in FEV1
(0.172, 0.213, and 0.275 L, respectively, compared with
0.071 L for placebo). Improvements in the peak change
from baseline in FEV1 and FVC were generally similar for FF
MDI 9.6 mg and FA 12 mg. However, at 30 min post-dosing
there was a transient reduction in FVC occurring for the
4.8- and 9.6-mg doses. At the next sampling time (1 h post-
dosing), the change from baseline had again increased and
values were similar for FF MDI 9.6 mg and FA 12 mg. The
differences between FF MDI 9.6 mg and FA 12 mg were not
statistically significant, but there was a small numeric
advantage with FA 12 mg. The mean change in FVC was
significantly greater with FF MDI than placebo at 1 h for
2.4 mg; 15 min, 1 h, and 2 h for 4.8 mg; and from 15 min
through 6 h and at 10 h for 9.6 mg (P  .039). Overall, the
mean changes in PEFR, tFEV1, and peak IC over time
showed a dose-related trend among the FF MDI doses that
was significantly different from placebo and that were
similar between FF MDI 9.6 mg and FA 12 mg. The mean
change in PEFR was significantly greater with FF MDI than
placebo at all doses and time points except for the 2.4-mg
dose at 10 h and 11.5 h (P  .042). For peak IC, the dif-
ferences between FF MDI 9.6 mg and FA 12 mg were small
and not statistically significant, although they showed a
small numeric advantage for FF MDI 9.6 mg. There was a
dose proportional increase in systemic exposure to for-
moterol observed with increasing doses of FF MDI as evi-
denced by the dose-related increases in AUC0e12 and Cmax
(Table 3), and FF MDI 9.6 mg demonstrated a similar
concentration-time profile to that of FA 12 mg (Figure 5).
Pharmacokinetic endpoints
Exposure of formoterol (AUC0e12 and Cmax) following
administration of FF MDI appeared to increase in a dose-
proportional manner across doses ranging from 2.4 to
9.6 mg. There was no obvious shift in Tmax. A comparison of
relative bioavailability of plasma formoterol concentrations
(with 90% confidence intervals) for the three FF MDI treat-
ment groups compared to FA 12 mg is presented in Table 4.
The AUC0et of formoterol following administration of
9.6 mg of FF MDI was similar to that of observed with
FA12 mg (34.0 and 36.1 pg h/mL, respectively). Further-
more, the Cmax of formoterol following administration of
9.6 mg of FF MDI was similar to that of observed with FA
12 mg (6.36 and 6.35 pg/mL, respectively). For AUC0e12, the
dose normalized estimated bioavailability in the FF MDI was
Figure 4 Mean change in forced vital capacity, peak expi-
ratory flow and inspiratory capacity over time by treatment
compared with test-day baseline (mITT efficacy population).
1332 D. Quinn et al.1.06 (90% CI: 0.91e1.23) for 2.4 mg; 0.90 (90% CI 0.78, 1.05)
for 4.8 mg, and 0.86 (90% CI 0.74, 0.99) for the 9.6 mg groups
relative to FA 12 mg. For Cmax the dose normalized esti-
mated bioavailability in the FF MDI 2.4 mg, 4.8 mg and 9.6 mg
groups relative to FA 12 mg was 1.50 (90% CI: 1.21e1.86),
1.02 (90%: CI 0.85 to 1.23) and 1.01 (90% CI: 0.84e1.22),respectively. Overall, the above results suggest that the
administration of 9.6 mg of FF MDI resulted in comparable
exposure to FA 12 mg. Mean t1/2 values of formoterol were
relatively consistent across treatments.
This study was not powered to assess bioequivalence;
however, the assessment of the ratios of unadjusted Cmax
and AUC of 9.6 mg of formoterol fumarate MDI vs. FA 12 mg
was important to guide the appropriate dose selection and
sample sizes for future studies. Unadjusted Cmax and
AUC0e12 ratios of 9.6 mg of FF MDI vs. FA 12 mg were 98% and
96.8%, respectively. The ratio between the two formula-
tions for these key assessments are within 100%  4% and
CI’s support bioequivalence for AUC0e12, but have limits
that are just outside traditional bioequivalence bounds for
Cmax. Although bioequivalence was not unequivocally
demonstrated, the bioavailability of FF MDI was generally
comparable to, or lower than that for open-label FA 12 mg.
Safety
Sixty-two TEAEs were reported, 17 events occurred
following treatment with placebo; 12, 10, and 6 events
after treatment with FF MDI 2.4 mg, 4.8 mg, and 9.6 mg,
respectively; and 17 events following treatment with FA
12 mg. Headache was the most frequently occurring TEAE.
As a system class, the most frequent events were respira-
tory in nature and included cough and dyspnea, but these
occurred more frequently in the placebo group. There were
no notable differences among TEAEs following each treat-
ment. Most of the TEAEs were mild or moderate and were
considered not related or unlikely to be related to study
treatment. A summary of the most frequent TEAEs is pro-
vided in Table 5. Two study patients experienced serious
adverse events (SAEs) (small intestinal obstruction and
exacerbation of COPD), both of which were considered to
be unrelated to study treatment. Three study patients were
withdrawn due to AEs (exacerbation of COPD, dyspnea, and
atrial fibrillation), all of which were considered to be un-
related to study treatment. One study patient experienced
tremor after the 9.6 mg dose. This event lasted approxi-
mately 6 h and was considered to be mild and probably
related to study drug. The patient recovered with no re-
sidual effects.
In general, changes in hematology, clinical chemistry,
and vital signs were small and no important trends were
noted between FF MDI treatment and either placebo or FA
12 mg treatment. There was no evidence of hypokalemia
and no study patient had a clinically significant abnormal
serum potassium value. Mean changes from baseline in
QTcF, and the number of study patients who experienced
clinically significant changes in QTcF were small, and no
differences or trends were noted between FF MDI treat-
ment and either placebo or FA 12 mg treatment.
Discussion
Formoterol fumarate (FA 12 mg) is well established in clin-
ical practice for the treatment of asthma and COPD. FF MDI
has been formulated using a proprietary porous-particle
engineering platform. The current study was undertaken to
describe the bronchodilatory efficacy and systemic
Table 3 Formoterol fumarate AUC0e12 and Cmax (mITT pharmacokinetic population).
FF MDI 2.4 mg FF MDI 4.8 mg FF MDI 9.6 mg FA 12 mg
Variable n Mean
(90% CI)
n Mean
(90% CI)
n Mean
(90% CI)
n Mean
(90% CI)
AUC0e12
(pg.hr/mL)
21 11.07
(6.32, 15.82)
21 18.53
(13.77, 23.29)
20 35.13
(30.28, 39.98)
23 38.67
(34.09, 43.25)
Cmax
(pg/mL)
21 1.63
(0.64, 2.61)
21 3.38
(2.40, 4.37)
20 6.14
(5.13, 7.14)
23 6.21
(5.26, 7.16)
AUC0e12 Z area under the curve for 0e12 h; Cmax Z maximum plasma concentration; FA Z Foradil Aerolizer; FF MDI Z formoterol
fumarate metered-dose inhaler.
Non-compartmental parameter estimates were analyzed using a repeated-measures ANOVA, in which treatment was a fixed effect,
within-patient errors were correlated, and between-patient errors were independent.
Figure 5 Mean concentration time plots for formoterol
fumarate by treatment group (mITT pharmacokinetic
population).
Formoterol fumarate porous particle MDI dose-ranging 1333exposure of a single dose at 3 dose levels of FF MDI in pa-
tients with moderate to severe COPD to identify a dose (s)
that provide (s) comparable bronchodilation and that does
not exceed the systemic exposure of FA 12 mg.
HFA MDIs formulated upon a porous-particle platform
using a spray-drying method provide a scaffold for
suspensions of inhaled drugs. The FF MDI evaluated in this
study is based on these porous particles of a
respirable aerodynamic size, comprised of dis-
tearoylphosphatidylcholine (DSPC) and calcium chlorideTable 4 Relative bioavailability comparison of plasma formote
FF MDI 2.4 mg FF MDI
Variable Estimate (90% CI) Estimat
AUC0e12 1.06 0.91, 1.23 0.90
Cmax 1.50 1.21, 1.86 1.02
AUC0e12 Z area under the curve for 0e12 h; Cmax Z maximum plas
fumarate metered-dose inhaler; mITT Z modified intent-to-treat; AU
Mean log PK parameters and 90% confidence intervals (CIs) of their ra
These estimates and CIs were exponentiated to give CIs on the relativ
bioavailability calculations were performed for each FF MDI group ve
alence were calculated from the parameters of the linear repeated m(CaCl2) at a 2:1 M ratio. When co-suspended with micron-
ized active pharmaceutical ingredient (API) crystals in HFA-
134a, they form a stable suspension in the MDI. Both the
DSPC and CaCl2 components are endogenous components of
human lung surfactant. In the humid environment of the
lung, the structure of the porous particles collapse and
dissolve in the lung fluid. As a result, the porous particles do
not appear to affect drug absorption, and as the findings of
this study suggest, FF MDI demonstrates comparable bron-
chodilation and PK profile compared with an approved
LABA, FA 12 mg. Benefits of the porous particle technology
include improved physical stability, the ability to formulate
at very low doses, consistent dose-to-dose performance,
high fine-particle fraction (FPF), and improved delivery of
drug to the lower respiratory tract with minimized
oropharyngeal exposure [4e6].
For the primary efficacy endpoint, mean change in FEV1
AUC0e12 from test day baseline, each dose of FF MDI showed
statistically significantly superior efficacy compared with
placebo (p < .001 for all 3 dose levels) with an apparent
doseeresponse relationship. The efficacy of FF MDI 9.6 mg
in terms of improvement in FEV1 was similar to that of FA
12 mg with nearly identical response curves over time.
Although both FF MDI 2.4 mg and 4.8 mg demonstrated
significantly greater improvements in FEV1 than placebo,
the magnitude of the improvements was substantially lower
than that observed with FA 12 mg.
The FF MDI 9.6 mg dose was shown to be statistically non-
inferior to FA 12 mg in terms of improvement from baseline
in FEV1 at all timepoints tested using the a priori defined
non-inferiority bound of 100 mL. On further analysis, therol fumarate (mITT pharmacokinetic population).
4.8 mg FF MDI 9.6 mg
e (90% CI) Estimate (90% CI)
0.78, 1.05 0.86 0.74, 0.99
0.85, 1.23 1.01 0.84, 1.22
ma concentration; FA Z Foradil Aerolizer; FF MDI Z formoterol
C0e12 Z area under the curve for 0e12 h.
tios were calculated from the mixed model analysis of variance.
e availability (rather than log relative availability) scale. Relative
rsus FA 12 mg. Ninety percent confidence intervals for bioequiv-
easures analysis.
Table 5 Summary of treatment-emergent adverse eventsa (safety population).
System organ class
preferred term
FF MDI 9.6 mg
(n Z 29)
FF MDI 4.8 mg
(n Z 32)
FF MDI 2.4 mg
(n Z 34)
FA 12 mg
(n Z 32)
Placebo
(n Z 33)
Respiratory, thoracic and mediastinal disorders
Cough 0 0 0 0 3
Dyspnea 0 1 1 1 2
Nervous system disorders
Headache 1 0 5 2 2
Skin and subcutaneous tissue disorders
Actinic keratosis 0 0 0 3 0
FA Z Foradil Aerolizer; FF MDI Z formoterol fumarate metered-dose inhaler.
a Occurring with a greater frequency than 3 study patients.
1334 D. Quinn et al.data support a non-inferiority bound of approximately
45 mL, which provides further assurance of the compara-
bility of the 9.6 mg dose to FA 12 mg. The 2.4 and 4.8 mg
doses were found to be inferior to FA 12 mg at almost every
time point assessed. In general, the secondary endpoints
(time to onset of effect, peak and trough FEV1, FVC, PEFR,
and peak IC) confirmed the findings of the primary
endpoint, with dose ordering of the 2.4 mg, 4.8 mg and
9.6 mg doses of FF MDI, and comparability of the 9.6 mg dose
of FF MDI to FA 12 mg.
Systemic exposure to formoterol from FF MDI demon-
strated a clear linear relationship across the assessed
dosage range. Formoterol fumarate MDI at a dose of 9.6 mg
demonstrated a comparable pharmacokinetic profile to FA
12 mg, with similar concentration-time plots and similar
AUC0e12 and Cmax. There was no evidence of a difference
between FF MDI and FA 12 mg in terms of the relationship
between formoterol exposure and spirometry response.
These data represent the first attempts to quantify the
dose-related efficacy of FF MDI delivered via a porous-
particle platform compared with open-label FA 12 mg in
patients with moderate to severe COPD. Since current best
clinical practices rely on the use of a LABA in combination
with a LAMA as first-line therapy for the long-term man-
agement of COPD, further research that focuses on these
questions regarding the porous particle platform for the
delivery of LAMA/LABA in combination should be
undertaken.
All 3 doses of FF MDI were found to be safe and well-
tolerated in this study. The safety profile for FF MDI was
similar to that of placebo and FA 12 mg. No important safety
trends or signals were noted for FF MDI in terms of AEs, QTc
changes, or changes in serum potassium or other laboratory
values.Study limitations
Although the study incorporated only a single-dose, under
these conditions, a single-dose is appropriate. However,
since there was no intermediate dose between 4.8 and
9.6 mg, and there was no separation between 2.4 and
4.8 mg, it is unclear if the minimal effective dose was
achieved. Because of the differences in delivery device, FA
12 mg was administered open-label. Whether this aspect ofthe study may have influenced the outcomes is undeter-
mined. The study enrolled patients with a clinical history of
COPD and functional reversibility to bronchodilator
administration. This is a specific sub-set of COPD patients,
therefore care should be taken in extrapolating the results
to clinical conditions other than those examined within this
study.
Conclusions
FF MDI 9.6 mg demonstrated significantly superior bron-
chodilator efficacy compared with placebo and comparable
bronchodilator efficacy compared with FA 12 mg. The 2.4-
and 4.8-mg doses of FF MDI showed bronchodilator efficacy
that was statistically significantly superior to placebo over
the 12-h post-dose period but those doses were generally
numerically inferior to FA 12 mg. However, further evalua-
tion of doses between 4.8 and 9.6 mg in subsequent studies
is warranted. FF MDI 9.6 mg demonstrated a comparable PK
profile to FA 12 mg. All 3 doses of FF MDI were safe and well-
tolerated with a safety profile similar to that of placebo and
FA 12 mg.
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